ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1101

Development of an Algorithm to Identify Sjögren’s Syndrome Patients in the French National Healthcare Claims Database

Valérie Devauchelle Pensec1, Laurent Chiche 2, Joe Zhuo 3, Isabelle Lavrard 4, Guillaume Desjeux 5 and Raphaele Seror 6, 1University Hospital of Brest, Brest, France, 2Hôpital Européen, Marseille, France, 3Bristol-Myers Squibb, Princeton, NJ, 4Bristol-Myers Squibb, Rueil-Malmaison, France, 5E-health Services Sanoïa, Digital CRO, Gémenos, France, 6Hopitaux universitaires Paris Sud, Kremlin-Bicetre, France

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Sjogren's syndrome and administrative databases

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Sjogren’s syndrome (SS) is a chronic autoimmune disease, consisting
of primary SS (pSS) when it presents alone and secondary or associated SS when
accompanied by other connective tissue diseases. Prevalence of primary SS ranges
between 10 and 90 cases per 100,000 people in Europe. However, there is a lack of efficient
algorithm that can be used in claim-based database to identify SS patients. Our objective
was to establish an algorithm that can be used to identify SS patients by using a sub-sample
of the French healthcare database claim.

Methods: Potential SS cases were identified based on ICD-10 codes (M35.0) when used for
SS-related hospitalization or chronic disease status allowing full expenditure reimbursement
codage, from 2005 to 2016. Reimbursements of at least one drug of interest, number of
specialist prescriptions, reimbursement of Schirmer’s test, procedures on salivary gland and
research of antinuclear antibody were identified as variables of interest to build an algorithm.
Patients having at least exclusion criteria of pSS ACR-EULAR classification criteria were
excluded. Patients with associated code of rheumatoid arthritis, juvenile arthritis, ankylosing
spondylitis, systemic lupus erythematosus, systemic sclerosis and other overlap syndromes,
based on ICD-10 codes or biological therapy reimbursements, were classified as secondary
SS. The onset of the disease was identified as the first occurrence of ICD-10 M35.0. A
cross-validation was performed by using a logistic regression to estimate the accuracy of 15
different “diagnosis” algorithms.

Results: Among the 447 potential SS patients identified, 44 were excluded, 267 patients
were classified as pSS and as 136 secondary SS. The most efficient algorithm to identify
pSS (with an accuracy of 0.94) was: ICD code of SS + at least 2 prescriptions of at least one
of the drugs of interest in 4 years before, or the 4 years after the first occurrence of the ICD
code of SS. For secondary SS, the best algorithm (with an accuracy of 0.89) was: ICD code
of SS + at least 2 prescriptions by a rheumatologist or an internal medicine physician both
before and after the first occurrence of the ICD code of SS. With these algorithms, estimated
prevalences were 29.5 per 100,000 for pSS and 8.30 per 100,000 for secondary SS in 2016.

Conclusion: Using a sub-sample of the French healthcare claims database, we developed,
two algorithms to efficiently identify primary and secondary SS patients. Further analysis is
planned to estimate at national-level prevalence and incidence of SS in France and analyze
healthcare consumption. In addition, these algorithms can potentially be adapted for claims
data in other countries.


Disclosure: V. Devauchelle Pensec, Bristol_myers Squibb, 2, CHUGAI, 2, Chugai Pharma France, 8, Roche, 2; L. Chiche, None; J. Zhuo, Bristol-Myers Squibb, 1, 3; I. Lavrard, Bristol-Myers Squibb, 1, Bristol-Myers Squibb, 3; G. Desjeux, E-health Services Sanoïa, 3; R. Seror, Bristol-Myers Squibb, 5, GlaxoSmithKline, 5, UCB, 5, Lilly, 5, Pfizer, 5.

To cite this abstract in AMA style:

Devauchelle Pensec V, Chiche L, Zhuo J, Lavrard I, Desjeux G, Seror R. Development of an Algorithm to Identify Sjögren’s Syndrome Patients in the French National Healthcare Claims Database [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/development-of-an-algorithm-to-identify-sjogrens-syndrome-patients-in-the-french-national-healthcare-claims-database/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-an-algorithm-to-identify-sjogrens-syndrome-patients-in-the-french-national-healthcare-claims-database/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology